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The Patnaik histologic grading system is commonly used to predict the behavior of cutaneous mast cell tumors (MCTs) in
dogs, but it is less useful for grade 2 MCTs because they exhibit considerable variation in biological behavior. In this
retrospective study, immunohistochemical staining for Ki-67, proliferating cell nuclear antigen (PCNA), and survivin and
a standardized argyrophilic staining of nucleolar organizer regions (AgNOR) protocol were performed on 121 archived
paraffin-embedded specimens of canine cutaneous MCTs, for which clinical follow-up data were available. Cox regression
models indicated that the Ki-67 score (hazard ratio, 1.92; P , .001) and mean AgNOR score (hazard ratio, 2.57; P , .001)
were significantly associated with Patnaik grade and survival time. A binary Ki-67 variable (cutoff point Ki-67 score 5 1.8)
was a significant predictor of survival for dogs with grade 2 MCTs. The estimated 1-, 2-, and 3-year survival probabilities for
dogs with grade 2 MCTs and Ki-67 scores less than 1.8 were 0.92, 0.86, and 0.77, respectively (SEs, 0.08, 0.14, and 0.23,
respectively; median not estimable). The corresponding survival probabilities for dogs with grade 2 MCTs and Ki-67 scores
higher than 1.8 were 0.43, 0.21, and 0.21, respectively (SEs, 0.19, 0.18, and 0.18, respectively; median survival time, 395 days).
No significant association was identified between survival and survivin score or PCNA score. This study shows that both
mean AgNOR score and Ki-67 score are prognostic markers for canine MCTs. The Ki-67 score can be used to divide Patnaik
grade 2 MCTs into 2 groups with markedly different expected survival times.
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M ast cell tumors (MCTs) are the most frequentlydiagnosed skin tumors of dogs, occurring at an
estimated incidence of 129 per 100,000 dogs.1 The
Patnaik histologic grading scheme2 is the most frequent-
ly used method to predict the biological behavior and
prognosis of an individual MCT. This grading scheme is
useful in predicting the behavior of generally benign
(grade 1) and malignant forms (grade 3) of the disease.
However, the Patnaik histologic grading scheme is less
useful for predicting the behavior of the intermediate
grade (grade 2) MCT because of the wide range of
behavior exhibited by these tumors. Most intermediate
grade MCTs have a benign clinical course and can be
cured by wide local excision. However, a proportion of
intermediate grade MCTs will metastasize, with esti-
mates of the metastatic rate varying between 5%3 and
22%4 and the rates of local recurrence varying between
5%3 and 11%.4 Most MCTs fall into this intermediate
grade category,5 and it is still difficult to accurately
predict how most MCTs are likely to behave and what
additional therapy, if any, should be given to these dogs.
For instance, if all intermediate grade tumors are treated
by local excision alone, a considerable number of the
tumors are being undertreated, whereas if all interme-
diate grade MCTs are treated with adjuvant systemic
treatment, then a large proportion of dogs would receive
unnecessary, and potentially harmful, therapy.
Veterinary pathologists may interpret the Patnaik
histologic grading scheme in different ways, and different
pathologists may assign different grades to the same
MCT. A quantitative and less subjective grading scheme
would therefore be of great clinical value.
Several studies have been performed in an attempt to
develop less subjective methods of predicting MCT
behavior and prognosis from analysis of formalin-fixed,
paraffin-embedded tumor tissue. These studies have
used assessment of various markers of cellular pro-
liferation, including argyrophilic staining of nucleolar
organizer regions (AgNOR),6–8 proliferating cell nuclear
antigen (PCNA),6,9 and Ki-67 indices.9 Of these pro-
liferation markers, only the Ki-67 index has been shown
to be a prognostic indicator for canine MCTs in-
dependent of Patnaik grade.9
All of these proliferation markers can be used to
estimate the numbers of cells that are undergoing cell
division. This estimate has been shown to be more
accurate than counting mitotic figures alone, because
these markers identify cells in the S phase and the M
phase of the cell cycle and have been shown to have
prognostic value in a number of different studies in both
humans and animals. PCNA is a member of the DNA
sliding clamp family of proteins, which are essential
components of the DNA replication system. PCNA helps
to coordinate the DNA replicating protein complex at the
replication fork and enhances DNA processivity for
replicative DNA polymerases, including the delta subunit
of DNA polymerase.10 This protein is expressed during
both the S and M phases of the cell cycle.
Ki-67 is a large (395-kDa) protein that, despite
extensive study, has no known function in the cell.11
Its subcellular localization and expression are tightly
regulated during the cell cycle, and it appears to be
necessary for progression of the cell cycle, because
inhibition of Ki-67 expression by antisense nucleotides
halts cell proliferation.12 The monoclonal antibody
MIB-1 is used to detect Ki-67 protein expression and
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has been used in studies in both dogs13,14 and humans,
as a measure of cell proliferation rate (as reviewed by
Brown and Gatter15). In some canine tumors, the
frequency of Ki-67 expression by neoplastic cells is
significantly associated with tumor prognosis.13,16–20
AgNOR counts have been used in many studies and
have been shown to provide clinically useful prognostic
information in both veterinary6,21–24 and human25,26
oncology. However, because many different histo-
chemical AgNOR staining techniques were used, it is
impossible to directly compare the results of these
studies among different laboratories. This difficulty has
prevented widespread adoption of this staining tech-
nique in routine diagnostic pathology practice, because
each laboratory would be required to validate its own
staining technique. To address this issue, an interna-
tional AgNOR standardization committee27 was formed
and published standardized and reproducible AgNOR
staining methods for a wide range of clinical samples. To
date, no studies in veterinary medicine have used these
standardized methods; therefore, the results of previous
studies of MCT prognosis and AgNOR staining counts
cannot be reliably compared or reproduced.
Tumor growth depends not only on the rate of
neoplastic cell proliferation but also on the rate of
neoplastic cell death. A tumor with a low proliferation
marker index and a low rate of cell death may be just as
aggressive as one that is proliferating quickly but has
a higher rate of cell death. Indeed, because carcino-
genesis is a multistep process that requires multiple
genetic mutations in individual cells, the inhibition of
apoptosis in the mutated cell is a necessary step for that
transformed cell to survive and continue to replicate.
Therefore, there has been an increased interest in
human oncology in the use of markers of apoptosis to
determine whether they too can be used to predict tumor
prognosis. Such has proved to be the case with a recently
identified member of the inhibitors of apoptosis family,
survivin.28 The inhibitors of apoptosis function as
endogenous inhibitors of caspase 9 and caspase 3, but
activation of other intracellullar signaling pathways also
may be involved. Evidence is accumulating that in-
dicates that survivin is involved in the maintenance of
chromosomal stability during mitosis,29 and that this
may be the main regulatory effect of survivin on the
cell cycle.30 Despite being largely undetectable in
most normal differentiated human tissues,31 survivin
has proved to be an almost universal tumor antigen,
being expressed in most human cancers that have
been examined for its presence.32 In many of these
cancers, it has proved to be an independent prognostic
marker. For example, patients with glioma that express
survivin at high concentrations have a much poorer
prognosis than those that express survivin at low
concentrations.33
In this study, we performed immunohistochemical
and histochemical staining of a large number of canine
MCTs to determine whether the frequency of expression
of inhibitor of apoptosis, survivin, and a number of
markers of cell proliferation (PCNA, Ki-67, and
AgNOR) can accurately predict canine MCT behavior.
Materials and Methods
Dog Selection
A retrospective study was performed on tissues submitted by
veterinary practices that were examined by 1 of 2 pathologists
(K.S., A.B.) at the Diagnostic Pathology Service of the Animal
Health Trust between 1997 and 1999 and resulted in a diagnosis of
a cutaneous MCT. Data retrieved from archived reports included
breed, sex, and age of the dog, grade of tumor, site of the primary
tumor, and histologic margins.5 The MCTs were graded according
to the system of Patnaik,2 and all histopathologic grading was
performed blinded to clinical outcome. Inclusion criteria were
based on those previously published.5 All dogs were treated by
veterinarians in general practice. All tumors were treated by
surgery, except for 5 dogs, who also received corticosteroid
therapy. Of these 5 dogs, 3 died as a result of their MCT. In total,
121 formalin-fixed, paraffin-embedded MCT tissue blocks were
identified and had sufficient tissue for additional sections to be
taken for analysis, and for which complete clinical follow-up data
were available.
For calculation of survival times, the date of MCT diagnosis,
rather than the date that the tumor was first noticed, was used as
the entry point, because for many dogs the date the owner noticed
the tumor was unknown. The date of censoring was September 1,
2000. Dogs who were reported to be dead from a MCT before that
date were recorded as events. Any animal that was reported to be
alive after that date, lost to follow-up before that date, or dead
from unrelated causes was censored. If there were multiple
submissions from a single dog, these submissions were carefully
evaluated. For a MCT from which more than 1 biopsy specimen
had been taken, relating either to its local regrowth or metastasis,
only the first report from that particular tumor was included in the
analysis. In the case of dogs with multiple MCTs (ie, neither
metastases nor local tumor regrowth), survival data were analyzed
considering each tumor as a separate event and by analyzing the
data with only the first tumor that was diagnosed.
Immunohistochemical Staining
Five-micrometer sections were taken from each paraffin block
and mounted onto positively charged, capillary gap glass slides.
Immunohistochemical staining for PCNA, Ki-67, and survivin
immunoreactivity was performed with an automated staining
system.a The positive control tissues for PCNA and Ki-67 were
formalin-fixed, paraffin-embedded sections of canine hyperplastic
lymph node. Formalin-fixed, paraffin-embedded sections of
a canine oral squamous cell carcinoma, a tumor that frequently
expresses survivin in humans,34 were used as positive controls for
survivin immunohistochemistry. For negative controls, the primary
antibody was replaced with antibody diluent. Antigen retrieval was
performed by incubating the mounted sections in a microwave
oven for a total of 10 minutes in a citrate buffer,b pH 6.0 (survivin
and PCNA), or EDTA buffer,c and pH 9.0 (Ki-67). Endogenous
peroxidase activity within the tissue sections was blocked with
hydrogen peroxide,d and sections were incubated for 30 minutes,
with the primary antibodies dilutede at the dilutions outlined in
Table 1. Detection of primary antibody binding was performed by
a 2-layer method and chromogen developed with diaminobenzi-
dine. Slides were counterstained with hematoxylin.
Histochemical Staining
The AgNOR staining technique used in this study was approved
by the International AgNOR Standardization Committee.27,35
Five-micrometer sections were made from each paraffin block
and mounted onto positively charged glass slides. Sections were
dewaxed, rehydrated, and immersed in 0.01M sodium citrate
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monohydrate, pH 6.0, and heated in a wet autoclave at 120uC for
20 minutes. Cooled sections were then washed in distilled water.
Silver stains were performed in the dark (at 37uC) by immersing the
slides in a 33% silver nitrate, 0.6% gelatin, and 0.33% formic acid
solution for 13 minutes. After staining, slides were washed,
dehydrated, and mounted.
Image Capture and Cell Counting
Histologic images were captured digitally at a magnification
of 2003 from equivalent regions of each stained tissue section, such
that the site selected was approximately one third of the distance
from the deep and lateral margins of the tumor mass. A computer
program (Tag and Count) was designed and writteng to enable
reliable counting of positive cells from each captured image. Cells
were counted with a pen and tablet input system. Counting was
performed without prior knowledge of clinical outcome.
Survivin Scoring
Positive survivin expression was assessed after optimization
of the technique with formalin-fixed, paraffin-embedded specimens
of canine oral squamous cell carcinoma, a tumor that expresses
survivin with high frequency in people.34 For survivin character-
ization, positive immunohistochemical staining was assessed by
a numeric scoring system for each captured image. Both nuclear
and cytoplasmic staining were assessed independently according
to the following scale: 0 indicates no positive staining cells; 1,
less than 0.1% of neoplastic mast cells exhibit positive staining;
2, 0.1–1% of neoplastic mast cells exhibit positive staining; 3, 2–
10% of neoplastic mast cells exhibit positive staining; 4, 11–50%
of neoplastic mast cells exhibit positive staining; and 5, 51–100%
of neoplastic mast cells exhibit positive staining. This scoring
system was used because most MCTs exhibited low concen-
trations of survivin immunoreactivity. Statistical analysis was
performed with individual categories on the scale and also
by grouping the scales into 0–10%, 11–50%, and 51–100%
categories.
Proliferation Marker Scoring
For evaluation of PCNA and Ki-67 expression, the total
numbers of mast cells and the total number of immunohistoche-
mical staining–positive mast cell nuclei were counted per captured
image. PCNA and Ki-67 scores were calculated as the percentage
of mast cell nuclei that exhibit positive immunohistochemical
staining within the image. The total number of AgNOR dots per
neoplastic mast cell nucleus was counted for each captured image,
up to a maximum of 200 mast cell nuclei, and the mean AgNOR
score per neoplastic cell nucleus was calculated.
Statistical Analysis
A preliminary examination of the data was performed with
frequency tables, histograms, and the medians and ranges for
different variables. Estimates of the survivor function were
displayed by Kaplan-Meier plots. Survival distributions were
summarized by the median survival time where estimable and, if
not estimable, by estimated 1-, 2-, and 3-year survival probabilities.
Cox regression analysis was used to determine any association
between time to death associated with MCTs (ie, death or
euthanasia of the animal as a direct result of MCT presence) and
possible prognostic indicators (ie, Patnaik grade and AgNOR,
survivin, PCNA, and Ki-67 scores). Survivin score was coded with
hierarchical indicator variables to reflect the inherent ordering of
the categories. Age at diagnosis was examined as a potential
confounder.
Variables were selected for inclusion in the model if they
significantly improved the fit (likelihood ratio x2 statistic P , .05).
The relationship between survival time and prognostic indicator
was displayed by Kaplan-Meier plots.36 Smoothing splines
were used to explore the functional form of the relationship
between time to death associated with MCTs and the continuous
prognostic indicator variables (AgNOR, PCNA, and Ki-67




The estimated 1-, 2-, and 3-year survival probabilities
were 0.83, 0.75, and 0.64, respectively (SEs, 0.17,
0.25, and 0.36, respectively). The mean age of the
dogs was 8.3 years (median, 8 years; range, 1–15 years).
Nineteen of the 121 dogs had multiple cutaneous MCTs.
A total of 121 dogs were analyzed after data checking:
72 of these dogs were still alive at the end of follow-up,
31 deaths were associated with the MCT, and 18 died
of causes unrelated to the MCT and were censored. Of
5 dogs who received prednisolone in addition to surgery,
2 were alive at the end of the study period and 3
were dead. Of the living dogs, 1 had a grade 1 MCT
and the other had a grade 2 MCT. Of the 3 dead dogs,
2 had grade 3 MCTs and 1 had a metastatic grade 2
MCT.
Patnaik Histologic Grade and Survival
Of the 121 dogs, 16 had grade 1 MCTs, 86 had grade
2 MCTs, and 19 had grade 3 MCTs; 17 dogs had 2
MCTs and 1 dog had 3 MCTs. Patnaik histologic
grade was found to be a highly significant predictor
of death associated with MCTs (P , .001). However,
because none of the dogs with Patnaik grade 1 tumors
died of the MCT during follow-up, the Cox regression
model gave unstable coefficients for grade 1 tumors.
The Kaplan-Meier survival plot for Patnaik grade
indicates that the ability of the different grades to
predict survival of this subset of dogs was consistent
with the originally published report2 and with other
studies3,4,6 (Fig 1).
Table 1. Antibody clone, source, and dilution used for immunohistochemical staining.
Antibody Clone Supplier Dilution Positive Control Tissue
PCNA PC10 Dako Corporation, Carpinteria, CA 1:2,000 Lymph node
Ki-67 MIB-1 Dako Corp 1:150 Lymph node
Survivin NB500-201 Novus Biologicals, Littleton, CO 1:600 Oral squamous cell carcinoma
PCNA, proliferating cell nuclear antigen.
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Frequency of Proliferation Marker Expression by
Neoplastic Mast Cells
The Ki-67 scores ranged from 0–22.2% (median,
1.0%). The mean AgNOR scores ranged from 1.13–4.1
(median, 1.7). The PCNA scores ranged from 3.2–83%
(median, 48.6%).
Univariable Cox regression models were used to
assess associations between the frequency of prolifera-
tion marker expression by neoplastic mast cells and
survival of dogs with cutaneous MCTs. This analysis
showed a significant association between the Ki-67 and
AgNOR scores and survival (Table 2). No significant
association occurred between PCNA score and survival.
The final multivariable Cox regression model for
continuous proliferation marker expression and survival
indicated that Ki-67 score (hazard ratio, 1.92; 95%
confidence interval, 1.44–2.56; P , .001) and mean
AgNOR score (hazard ratio, 2.57; 95% confidence
interval, 1.44–4.60; P , .001) were significantly associ-
ated with survival time of dogs with MCTs.
Smoothing splines indicated that the hazard ratio
increased after 1% for Ki-67 score and that the hazard
ratio increased after a mean of 1.8 was reached for mean
AgNOR score (data not shown). With these values as
cutoff points, binary variables for Ki-67 and AgNOR
scores were placed into a Cox regression model. This
analysis indicated that although both scoring systems
were significantly associated with survival, Ki-67 ex-
pression (hazard ratio, 3.77; 95% confidence interval,
1.65–8.64; P 5 .002) was a better predictor of death
associated with MCT than AgNOR score (hazard ratio,
2.59; 95% confidence interval, 1.14–5.85; P 5 .022).
Four (27%) of 15 Patnaik grade 1 tumors had a Ki-67
value greater than 1.8, compared with 14 (20%) of 70
Patnaik grade 2 tumors, and 8 (50%) of 16 grade 3
tumors. Ki-67 values were only available for 101 dogs
because of tissues repeatedly floating off the slides
during antigen retrieval. Kaplan-Meier survival plots for
canine MCTs categorized by binary variables for Ki-67
score with a cutoff value of 1% (Fig 2), and for mean
AgNOR score with a cutoff 1.8 (Fig 3), are shown.
The prognostic value of Ki-67 scores and mean
AgNOR scores were determined for a subset of the
MCTs that represented Patnaik grade 2 MCTs (85 dogs).
Smoothing splines indicated that within the Patnaik
grade 2 subset, in contrast to the smoothing splines
described herein that were created for the dog population
that covered all Patnaik grades, a more suitable cutoff
point for Ki-67 was 1.8 (data not shown). In this Patnaik
grade 2 subset, the AgNOR count cutoff point remained
1.8. Cox regression analysis indicated that only the binary
Ki-67 variable was a significant predictor of survival of
dogs with medium grade MCTs (hazard ratio, 11.1; 95%
confidence interval, 3.41–36.2; P , .001). The estimated
Table 2. Univariate results for proliferation markers




(95% CI) P Valuea
Ki-67 score 0.241 (0.051) 1.27 (1.15–1.41) , .001
Mean AgNOR
score
0.982 (0.285) 2.67 (1.53–4.67) .002
PCNA score 0.019 (0.012) 1.02 (1.00–1.04) .108
AgNOR, argyrophilic staining of nucleolar organizer regions; CI,
confidence interval; PCNA, proliferating cell nuclear antigen.
aP values calculated using the likelihood ratio test.
Fig 1. Kaplan-Meier survival plot for canine mast cell tumor
categorized by Patnaik grade.
Fig 2. Kaplan-Meier survival plot for canine mast cell tumors
categorized by binary Ki-67 score with a cutoff value of 1%.
Fig 3. Kaplan-Meier survival plot for canine mast cell tumors
categorized by binary mean argyrophilic staining of nucleolar
organizer regions score with a cutoff value of 1.8.
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1-, 2-, and 3-year survival probabilities for dogs with
grade 2 MCTs and Ki-67 scores greater than 1.8
were 0.92, 0.86, and 0.77, respectively (SEs, 0.08, 0.14
and 0.23, respectively; median not estimable). The
corresponding survival probabilities for dogs with grade
2MCTs andKi-67 scores greater than 1.8 were 0.43, 0.21,
and 0.21, respectively (SEs, 0.19, 0.18, and 0.18, re-
spectively; median survival, 395 days). A Kaplan-Meier
survival plot for Patnaik grade 2 MCTs categorized by
binary Ki-67 score with a cutoff value of 1.8 is shown in
Figure 4.
Expression of Survivin by Neoplastic Mast Cells
Immunohistochemical staining of a variety of forma-
lin-fixed, paraffin-embedded canine tissues with anti-
survivin antisera was performed with an array of 20
histologically normal canine tissues. As expected, this
procedure identified positive cytoplasmic staining in
small populations of lymphocytes within lymphoid
follicles of the spleen and lymph nodes, and within
epithelial cells at the base of mucosal crypts within the
small and large intestine. As expected, no positive
immunohistochemical staining was evident within tissue
sections of heart, lung, liver, kidney, brain, pancreas,
thyroid gland, adrenal gland, stomach, skeletal muscle,
peripheral nerve, salivary gland, skin, tongue, esophagus
and trachea. Neoplastic epithelial cells throughout
a sample of oral squamous cell carcinoma exhibited
moderate to intense positive cytoplasmic and variable
nuclear immunohistochemical staining for survivin
(Fig 5). This finding was subsequently used as a positive
control in later experiments. Negative controls were
performed by omitting the primary antibody.
Neoplastic mast cells in most dogs with MCT
exhibited positive nuclear survivin staining, cytoplasmic
survivin staining, or both (Fig 6; Table 3).
Cox regression analysis of this immunohistochemical
data for survivin expression indicated no significant
association between survival and the frequency of
survivin expression by neoplastic mast cells, or between
survival and subcellular location of survivin expression
within the neoplastic mast cells (data not shown).
Association Between Age and Multiplicity of Tumors
and Survival of Dogs with Cutaneous MCTs
In this population of dogs with MCTs, a significant
association between survival and age at diagnosis was
identified (hazard ratio, 1.19; 95% confidence interval,
1.03–1.38; P 5 .015). However, no association was
found between survival and the number of MCTs that
any 1 dog developed (hazard ratio, 0.91; 95% confidence
interval, 0.32–2.59; P 5 .850).
Discussion
A large group of canine cutaneous MCTs were
examined, with a number of markers of cell proliferation
and an inhibitor of apoptosis (survivin), to determine
whether these markers would have prognostic value for
survival after local treatment of MCTs. This was a large
study, and the methods used should be reproducible and
repeatable in any laboratory suitably equipped for
performing immunohistochemical staining of paraffin-
embedded tissues. Indeed, by assessing the proliferation
marker index in a single digital microscopic image
obtained from a standardized, selected area of the
tumor, rather than obtaining multiple digital micro-
scopic images of the tumor mass as has been performed
in other studies,9 these techniques should be relatively
simple to incorporate into the routine diagnostic
pathology laboratory workflow.
The most important finding of this study was that it
is possible to divide intermediate MCTs on the basis
of Ki-67 scores. Among dogs with Patnaik grade 2
MCTs, those with a Ki-67 score greater than 1.8 had
substantially lower estimated survival probabilities at
1, 2, and 3 years than dogs with a Ki-67 score less
than 1.8. This finding confirms and extends similar
findings that were evident in a smaller study by Abadie
et al.9 However, the data reported represents the first
study to directly assess survival for a large numbers of
dogs with MCTs with a broad range of different
Fig 4. Kaplan-Meier survival plot for Patnaik grade 2 mast cell
tumors categorized by binary mean Ki-67 score with a cutoff value
of 1.8. Fig 5. Survivin immunoreactivity by neoplastic epithelial cells of
a canine oral squamous cell carcinoma. Neoplastic cells exhibit
moderate positive immunohistochemical staining for survivin
within the nucleus and cytoplasm (rabbit anti-human survivin,
counterstained with hematoxylin, 340 objective lens).
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markers. We are currently performing a prospective
study to determine whether a Ki-67 score of 1.8 can be
used as a cutoff value in a larger series of intermediate
grade MCT.
Interestingly, there were more grade 1MCTs above the
Ki-67 score cutoff point of 1 than grade 2MCTs. Of these
dogs with grade 1 MCTs, most had multiple MCTs, but
all survived beyond the end of the study. Therefore, it is
possible that the neoplastic cells in the dogs with multiple
grade 1MCTs are different from those lesional neoplastic
mast cells in dogs with solitaryMCTs. For instance, there
may be different cellular signaling pathways (eg, tyrosine
kinase receptor–mediated pathways other than c-KIT)
affected within these 2 groups of neoplastic cells that
could account for the differences in growth fraction,
without increasing the likelihood of them recurring or
metastasizing. Alternatively, the rate of tumor cell death
by apoptosis may be higher in grade 1 MCTs than in
some grade 2 MCTs. Additional work is needed to
dissect the signaling pathways involved in MCT carcino-
genesis, and different signaling pathways may be altered
in different MCT subsets.
Similar to previous studies,6,7 lower AgNOR scores
were associated with longer survival times in dogs with
MCTs, but could not predict clinical behavior in-
dependent of the Patnaik histologic grade. This finding
greatly reduces the usefulness of the assay, because
Patnaik grade 2 MCTs are the most frequently
encountered histologic subtype and AgNOR scores do
not provide more prognostic information than is already
provided by the Patnaik histologic scoring system.
However, this is the first companion animal study to
use the standardized, internationally recognized Ag-
NOR staining protocol.27,35 The need for a standardized
AgNOR staining protocol has been recognized in
human medicine, in which it was found that AgNOR
score values could not be replicated among different
laboratories due to differences in AgNOR staining
techniques. Without standardization of this technique,
these studies cannot be translated from a research
environment into widespread clinical diagnostic prac-
tice, because each laboratory would be required to
perform their own studies to determine the equivalent
AgNOR scores for their specific staining protocol. The
results of this study will be directly comparable to any
future studies that also use the standardized AgNOR
staining protocols. Failure to find any association
between PCNA score and MCT prognosis confirms
similar findings in smaller previous studies.6,9
In the study population, only 5 dogs received
adjunctive chemotherapy (ie, prednisolone). Of these
dogs, 2 lived and 3 died. The 3 who died had much
more aggressive disease (grade 3 MCTs or metastatic
grade 2 MCTs), compared with those who were given
adjunctive chemotherapy and lived (a grade 1 MCT and
a grade 2 MCT). Therefore, the use of chemotherapy in
these dogs is unlikely to have skewed the results of these
analyses.
Table 3. Immunohistochemical detection of survivin expression in neoplastic cells of canine mast cell tumors.
Frequency of Survivin-Positive Neoplastic Cellsa
0 1 2 3 4 5
Nuclear survivin expression 22 12 31 28 18 3
Cytoplasmic survivin expression 44 20 11 13 12 14
a For frequency of survivin-positive neoplastic cells, 0 indicates no positive staining cells; 1, less than 0.1% of mast cells exhibit positive
staining; 2, 0.1–1% of mast cells exhibit positive staining; 3, 2–10% of mast cells exhibit positive staining; 4, 11–50% of mast cells exhibit
positive staining; and 5, 51–100% of mast cells exhibit positive staining.
Fig 6. Survivin immunoreactivity in a subset of neoplastic mast cells from a Patnaik grade 2 mast cell tumor. A subset of neoplastic mast
cells exhibit mild to moderate positive immunohistochemical staining of nuclei (a) and weak staining of the cytoplasm (b) for survivin (rabbit
anti-human survivin, counterstained with hematoxylin, 340 objective lens).
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This study is the first to demonstrate immunohisto-
chemical expression of survivin by neoplastic cells in
a companion animal species. We have found that the
antisera used in this study cross-reacts with a recombi-
nant canine survivin by Western blot analysis (data not
shown), which is consistent with the demonstration of
the expected tissue staining profile within multiple
normal canine tissues and in dogs with canine oral
squamous cell carcinoma. In some human cancers,
survivin expression by the neoplastic cells is closely
associated with prognosis and, in some cases, response
to treatment.37 In this study, survivin expression was not
found to be an independent prognostic factor for canine
cutaneous MCTs and had no value in predicting the
clinical outcome of disease. The overall concentration
and frequency of expression of survivin by the neoplastic
mast cells was low. Therefore, it is unlikely that any
survivin-targeted therapies that are developed in the
future will be of clinical benefit in the treatment of
canine MCTs. However, this study showed that neo-
plastic cells (including neoplastic epithelial cells within
squamous cell carcinoma), and some normal adult cells,
exhibit immunoreactivity for survivin in dogs. Addi-
tional studies will be necessary to determine whether
expression of survivin is associated with clinical behav-
ior or response to treatment in other cancers of com-
panion animal species.
Clearly, there is still a need to use the standard Patnaik
histologic grading scheme to identify the grade (1–3) of an
individual MCT, because this is the most rapid and cost-
effective way to broadly predict clinical behavior of these
tumors. However, this study indicates that if the tumor is
of intermediate grade, additional prognostic information
may be gained by determining theKi-67 score. Additional
studies are in progress in this laboratory, with larger
numbers of intermediate grade MCTs, to determine the
clinical usefulness of Ki-67 expression in predicting the
clinical behavior of these tumors.
Footnotes
aDako Techmate, Dako Corporation, Carpinteria, CA
b ChemMate Target Retrieval Solution, Dako Corporation,
Carpinteria, CA
c ChemMate Target Retrieval Solution, Dako Corporation,
Carpinteria, CA
d ChemMate Target Retrieval Solution, Dako Corporation,
Carpinteria, CA
eChemMate Antibody Diluent, Dako Corporation, Carpinteria,
CA
f Envision system, Dako Corporation, Carpinteria, CA
gRealbasic software, version 5.2.4, Mac OS10.2, Austin, TX
h Insightful, 2001, Seattle, WA
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